OST-tADC

NEW YORK--( BUSINESS WIRE )-- OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”) , a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company’s proprietary SiLinker™ technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will target Breast, Lung and Gastric Cancer; and Ovarian, Fallopian Tube and Primary Peritoneal Cancer, respectively. The Company is advancing its tADC platform through successive product development de-risking milestones and intends to out-license certain therapeutic candidates and components that are strategic to potential partners’ pipelines – particularly the ph-sensitive SiLinker™. The Company’s first tADC asset OST-tADC-FRα-H has achieved proof of concept in animal models of ovarian cancer. With the additional two constructs now added to the pipeline, the Company is positioning itself to become a key provider of intellectual property for new therapeutic product development to partners. All while continuing to focus its internal resources on bringing to market the OST-HER2 off-the-shelf immunotherapy cancer vaccine platform for canines with osteosarcoma, and for humans with osteosarcoma and other HER2 positive cancers such as breast cancer and colorectal cancer. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads. For more information, please visit www.ostherapies.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled “Risk Factors” of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the “SEC”) on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

OS Therapies 将通过一次 640 万美元的首次公开募股（IPO）在纽约证券交易所上市，利用这笔资金推进其免疫疗法和抗体药物偶联物（ADC）计划。 该公司一年前曾预期进行 1000 万美元的 IPO，但后来被搁置。昨天，OS Therapies 确认将在今天上午加入股市，以每股 4 美元的价格发行 160 万股。 IPO 应带来 640 万美元的毛收入，或在扣除承销折扣和佣金后为 600 万美元，公司在 6 月 31 日的公告中表示。如果承销商选择在 45 天内以相同价格购买额外的 24 万股，这一数字还有可能增加 96 万美元。 OS Therapies 一年前曾预期进行 1000 万美元的 IPO。（jxfzsy/iStock/Getty Images Plus） 资金的优先用途将是 OS Therapies 两个现有项目的临床开发。其中之一，OST-HER2，已经在临床试验中。OST-HER2 利用 HER2 生物工程改造的细菌 Listeria monocytogenes 来触发对表达 HER2 的癌细胞的免疫反应。 该公司在 6 月份公布了 OST-HER2 在切除复发性骨肉瘤患者中的 2b 期试验的初步数据，当时表示显示一年无事件生存率为 32.5%。 Actuate 披露了 5000 万美元的 IPO 计划，用于资助进一步的癌症药物试验 该项目还在“主要在乳腺癌患者中”完成了 OST-HER2 的 1 期研究，并在各种乳腺癌模型中显示出强大的临床前疗效数据，公司指出。 OS Therapies 的另一个主要重点是 OST-tADC，公司将其描述为一种下一代 ADC 平台，旨在“在肿瘤微环境中选择性释放多种治疗剂，该环境的 pH 值低于身体的其他部位。” 到目前为止，该公司已经在癌症小鼠模型中对 OST-tADC 进行了初步的安全性和有效性概念验证测试。 公司补充说，IPO 的剩余资金将用于“发现和开发新的候选产品，以及用于营运资本和其他一般公司用途”。 在 600 万美元的规模下，OS Therapies 的 IPO 与今年大多数生物技术 IPO 相比显得微不足道，这些 IPO 的规模通常至少达到八位或九位数，并且通常在知名度更高的纳斯达克交易所上市。CG Oncology 继续以 2024 年迄今为止的 3.8 亿美元的发行量位居首位，开启了今年的市场。 参考资料： https://www.fiercebiotech.com/biotech/os-therapies-refiles-modest-6m-ipo-fund-phase-2-her2-drug-preclinical-adcs 识别微信二维码，添加生物制品圈小编，符合条件者即可加入 生物制品微信群！ 请注明：姓名+研究方向！ 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。